Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATNM Actinium Pharmaceuticals	$1.54 -2.5%	$1.46	$1.03 ▼ $8.64	$48.04M	-0.24	499,055 shs	75,412 shs
DTIL Precision BioSciences	$4.86 -1.2%	$4.93	$3.61 ▼ $13.27	$53.89M	1.55	183,916 shs	27,941 shs
MRKR Marker Therapeutics	$1.55 +28.1%	$1.16	$0.95 ▼ $5.99	$17.54M	1.29	72,380 shs	2.01 million shs
QNCX Quince Therapeutics	$1.03 -1.0%	$1.08	$0.51 ▼ $2.45	$46.83M	0.83	288,521 shs	102,268 shs

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATNM Actinium Pharmaceuticals	0.00%	-6.10%	-0.65%	+45.28%	-81.10%
DTIL Precision BioSciences	0.00%	+6.11%	-15.48%	-2.80%	-62.33%
MRKR Marker Therapeutics	0.00%	+35.98%	+24.02%	+6.91%	-59.94%
QNCX Quince Therapeutics	0.00%	-7.21%	-2.83%	-28.97%	+24.10%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ATNM Actinium Pharmaceuticals	1.3787 of 5 stars	3.4	0.0	0.0	1.7	0.0	0.6
DTIL Precision BioSciences	3.7888 of 5 stars	3.5	2.0	4.6	1.2	1.7	0.6
MRKR Marker Therapeutics	4.1782 of 5 stars	3.8	3.0	3.9	3.3	0.8	0.6
QNCX Quince Therapeutics	3.8785 of 5 stars	3.6	5.0	0.0	4.1	1.7	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ATNM Actinium Pharmaceuticals	2.75	Moderate Buy	$4.00	159.74% Upside
DTIL Precision BioSciences	3.00	Buy	$47.00	867.08% Upside
MRKR Marker Therapeutics	3.50	Strong Buy	$13.17	749.35% Upside
QNCX Quince Therapeutics	3.29	Buy	$8.00	676.70% Upside

Current Analyst Ratings Breakdown

Latest MRKR, ATNM, DTIL, and QNCX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/21/2025	DTIL Precision BioSciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$60.00 ➝ $60.00
5/12/2025	ATNM Actinium Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$4.00 ➝ $4.00
4/28/2025	ATNM Actinium Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$4.00 ➝ $4.00
4/1/2025	ATNM Actinium Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$4.00 ➝ $4.00
4/1/2025	MRKR Marker Therapeutics	WBB Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Strong-Buy ➝ Strong-Buy	$12.50 ➝ $12.50
3/28/2025	DTIL Precision BioSciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$60.00 ➝ $60.00
3/25/2025	ATNM Actinium Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$4.00 ➝ $4.00
3/25/2025	QNCX Quince Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$12.00 ➝ $4.00
3/24/2025	QNCX Quince Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$10.00
3/19/2025	DTIL Precision BioSciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$60.00 ➝ $60.00
3/18/2025	ATNM Actinium Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$4.00 ➝ $4.00

(Data available from 6/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ATNM Actinium Pharmaceuticals	$81K	593.11	N/A	N/A	$1.31 per share	1.18
DTIL Precision BioSciences	$51.14M	1.05	N/A	N/A	$4.53 per share	1.07
MRKR Marker Therapeutics	$6.59M	2.66	N/A	N/A	$1.58 per share	0.98
QNCX Quince Therapeutics	N/A	N/A	N/A	N/A	$1.98 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ATNM Actinium Pharmaceuticals	-$48.82M	-$1.39	N/A	N/A	N/A	N/A	-100.85%	-47.89%	N/A
DTIL Precision BioSciences	-$61.32M	-$2.01	81.01	N/A	N/A	11.48%	-23.69%	-6.98%	7/30/2025 (Estimated)
MRKR Marker Therapeutics	-$8.24M	-$1.33	N/A	N/A	N/A	-179.74%	-89.63%	-71.62%	8/13/2025 (Estimated)
QNCX Quince Therapeutics	-$31.39M	-$1.39	N/A	N/A	N/A	N/A	-53.27%	-22.73%	8/12/2025 (Estimated)

Latest MRKR, ATNM, DTIL, and QNCX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/15/2025	Q1 2025	DTIL Precision BioSciences	-$0.43	-$2.21	-$1.78	-$2.21	$5.00 million	$0.03 million
5/13/2025	Q1 2025	QNCX Quince Therapeutics	-$0.24	-$0.34	-$0.10	-$0.34	N/A	N/A
3/31/2025	Q4 2024	MRKR Marker Therapeutics	-$0.28	-$0.42	-$0.14	-$0.42	$5.25 million	$1.22 million
3/26/2025	Q4 2024	DTIL Precision BioSciences	-$2.09	-$3.20	-$1.11	-$2.22	$4.28 million	$3.47 million
3/24/2025	Q4 2024	QNCX Quince Therapeutics	-$0.19	-$0.28	-$0.09	-$0.28	N/A	$0.17 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ATNM Actinium Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
DTIL Precision BioSciences	N/A	N/A	N/A	N/A	N/A
MRKR Marker Therapeutics	N/A	N/A	N/A	N/A	N/A
QNCX Quince Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ATNM Actinium Pharmaceuticals	N/A	10.25	10.25
DTIL Precision BioSciences	0.34	9.22	9.22
MRKR Marker Therapeutics	N/A	3.15	3.15
QNCX Quince Therapeutics	0.33	9.53	9.53

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ATNM Actinium Pharmaceuticals	27.50%
DTIL Precision BioSciences	37.99%
MRKR Marker Therapeutics	22.39%
QNCX Quince Therapeutics	30.75%

Insider Ownership

Company	Insider Ownership
ATNM Actinium Pharmaceuticals	6.00%
DTIL Precision BioSciences	4.50%
MRKR Marker Therapeutics	14.50%
QNCX Quince Therapeutics	20.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ATNM Actinium Pharmaceuticals	30	31.20 million	29.32 million	Optionable
DTIL Precision BioSciences	200	11.09 million	7.36 million	No Data
MRKR Marker Therapeutics	60	11.32 million	9.16 million	Not Optionable
QNCX Quince Therapeutics	60	45.47 million	36.61 million	Optionable

MRKR, ATNM, DTIL, and QNCX Headlines

Recent News About These Companies

Quince Therapeutics: Data In Ataxia-Telangiectasia Scheduled For Early 2026

May 15, 2025 | seekingalpha.com

Quince Therapeutics Provides Business Update and Reports First Quarter 2025 Financial Results

May 14, 2025 | finance.yahoo.com

Quince Therapeutics to Present at Citizens Life Sciences Conference

April 30, 2025 | businesswire.com

Quince Therapeutics to Present at Jones Healthcare and Technology Innovation Conference

April 3, 2025 | businesswire.com

Analysts Are Bullish on Top Healthcare Stocks: Quince Therapeutics (QNCX), Lucid Diagnostics (LUCD)

March 27, 2025 | markets.businessinsider.com

Quince Therapeutics Provides Business Update and Reports Fiscal Year 2024 Financial Results

March 24, 2025 | businesswire.com

Oppenheimer Initiates Coverage of Quince Therapeutics (QNCX) with Outperform Recommendation

March 24, 2025 | msn.com

Quince Therapeutics to Host Investor Webinar Today Focused on Addressing the High Unmet Need in Ataxia-Telangiectasia

February 7, 2025 | businesswire.com

Quince Therapeutics to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference

February 5, 2025 | businesswire.com

Quince Therapeutics gets USPTO notice of allowance in Ataxia-Telangiectasia

February 4, 2025 | markets.businessinsider.com

Quince Therapeutics secures USPTO nod for A-T treatment patent

February 4, 2025 | msn.com

Quince Therapeutics Receives Notice of Allowance Covering Innovative Method of Use for Lead Indication Ataxia-Telangiectasia

February 4, 2025 | businesswire.com

Quince Therapeutics Announces Frontiers in Neurology Publication of Long-Term Safety of EryDex in Pediatric Patients with Ataxia-Telangiectasia

January 27, 2025 | finance.yahoo.com

Quince Therapeutics Appoints Renowned Pediatric Neurologist Dr. William Whitehouse to Scientific Advisory Board

January 24, 2025 | finance.yahoo.com

Quince Therapeutics initiated with a Buy at Brookline

December 19, 2024 | msn.com

Brookline Capital Initiates Coverage of Quince Therapeutics (QNCX) with Buy Recommendation

December 19, 2024 | msn.com

Quince Therapeutics Share Price (QNCX.US)

November 18, 2024 | lse.co.uk

Quince Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results

November 13, 2024 | businesswire.com

Quince Therapeutics Presents Data from Prior Phase 3 ATTeST Clinical Trial at 2024 International Congress for Ataxia Research

November 13, 2024 | finance.yahoo.com

Quince Therapeutics presents safety data from ATTeST trial at CNS meeting

November 13, 2024 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

MRKR, ATNM, DTIL, and QNCX Company Descriptions

Actinium Pharmaceuticals NYSE:ATNM

$1.54 -0.04 (-2.53%)

Closing price 05/30/2025 04:00 PM Eastern

Extended Trading

$1.56 +0.01 (+0.97%)

As of 08:26 AM Eastern

Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML). The company focuses on advancing its development for product candidate Actimab-A, a therapeutic agent that has demonstrated potential activity in r/r AML patients. In addition, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies. Its Iomab-ACT, a next generation conditioning candidate, is being developed for improving patient access and outcomes for curative cell and gene therapies. Further, the company's research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company holds approximately 235 patents and patent applications, including various patents related to the manufacture of the isotope Ac-225 in a cyclotron. The company is based in New York, New York.

Precision BioSciences NASDAQ:DTIL

$4.86 -0.06 (-1.22%)

Closing price 05/30/2025 04:00 PM Eastern

Extended Trading

$4.70 -0.16 (-3.21%)

As of 08:30 AM Eastern

Precision BioSciences, Inc., an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA. In addition, it develops PBGENE-NVS for sickle cell disease/beta thalassemia for insertion; PBGENE-DMD (excision) for duchenne muscular dystrophy; PBGENE-LL2 (insertion), a liver directed target; PBGENE-LL3, a central nervous system directed target; and iECURE-OTC (insertion) for ornithine transcarbamylase deficiency. The company has license and collaboration agreement with Caribou Biosciences, Inc.; license agreement with TG Cell Therapy, Inc. to develop, manufacture, and commercialize azer-cel for autoimmune diseases and other indications outside of cancer; development and license agreement with Eli Lilly and Company for the research and development of potential in vivo therapies for genetic disorders; Cellectis S.A.; iECURE, Inc. to develop ARCUS-based gene-insertion therapies; Duke University; and Novartis Pharma AG to discover and develop in vivo gene editing products. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.

Marker Therapeutics NASDAQ:MRKR

$1.55 +0.34 (+28.12%)

Closing price 05/30/2025 04:00 PM Eastern

Extended Trading

$1.54 -0.01 (-0.79%)

As of 08:40 AM Eastern

Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens. The company also develops MT-401-OTS for the treatment of acute myeloid leukemia; and MT-601 to treat lymphoma and pancreatic cancer. Marker Therapeutics, Inc. is headquartered in Houston, Texas.

Quince Therapeutics NASDAQ:QNCX

$1.03 -0.01 (-0.96%)

Closing price 05/30/2025 04:00 PM Eastern

Extended Trading

$1.04 +0.01 (+0.97%)

As of 08:03 AM Eastern

Quince Therapeutics, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene. Its AIDE technology platform, a drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells, as well as consists of an automated equipment the RCL, a sterile single-use consumable treatment kit comprising EryKit, Syringe Kit, drugs, and process solutions. The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. Quince Therapeutics, Inc. was incorporated in 2012 and is headquartered in South San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time